An analysis from business intelligence provider GBI Research titled “Frontier Pharma: Parkinson’s Disease — Identifying and Commercializing First-in-Class Innovation,” claims the current Parkinson’s disease (PD) treatment market relies on neuromodulators, and even though symptoms might be soothed, no neuromodulator has demonstrated neuroprotective properties to prevent or even slow…
A recent study published in JAMA Neurology suggested an association between weight loss in patients with early Parkinson’s disease and rapid disease progression. Weight loss is usual in patients with Parkinson’s disease (PD), but these new findings indicate that weight loss early in the disease’s progression reflects a more serious form…
Cynapsus Therapeutics, Inc., a Toronto-based specialty pharmaceutical company, and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced they are collaborating to incorporate wearable device technology and “big data” approaches into Cynapsus’ pivotal Phase 3 clinical study of APL-130277, a fast-dissolving, sublingual formulation of the drug apomorphine to treat…
A recent article in the Harvard Gazette suggests dance as a potential treatment for neurodegenerative disorders such as Parkinson’s disease (PD). Imaging studies have identified several brain regions involved in the complex, rhythmical, and coordinated movements that constitute dance. The motor cortex is — as with other kinds of voluntary…
A new study from the German Center for Neurodegenerative Diseases, published in the journal BRAIN, sheds new light on the processes leading to aggregation of the protein αlpha-synuclein in the brain of patients with Parkinson’s disease (PD). It has been proposed that the aggregates propagate in a fashion similar to prions,…
Contrary to recent evidence, new research has found no positive correlation between anticholinergic medication intake and a higher risk for dementia in Parkinson’s disease (PD) patients. The study is titled “Anticholinergic Load: Is there a Cognitive Cost in Early Parkinson’s Disease?” and appears in the Journal…
Evidence has shown a potential connection between chronic hepatitis C virus (HCV) infection and neurological and psychiatric disorders such as Parkinson’s disease (PD). In a recent study, investigators sought to determine if the disease was, in fact, a significant risk factor for Parkinson’s development. Their findings, in a study…
A recent study shows that patients with Parkinson’s disease (PD) have a dysfunctional brain reward anticipation response — a finding likely linked to the decreased motivational state that can afflict PD patients. The deficit in dopaminergic signaling that underlies PD affects more than just motor skills. Depression, apathy, and sleep disorders also frequently…
Parkinson’s News Today regularly reports the latest news on clinical trials, state-of-the-art research, and events related to Parkinson’s disease. With 2015 at a close, Parkinson’s News Today brings you the past year’s Top 10 Parkinson’s Disease Stories as determined by the number of views given each article by readers. No.
Amarantus BioScience Holdings, Inc. (AMBS) received a Notice of Allowance from the U.S. Patent and Trademark Office covering the use of 5HT1A in combination with 5HT1B agonists, including the clinical Phase 2b stage drug eltoprazine, to treat levodopa-induced dyskinesia (PD-LID) in Parkinson’s disease (PD). The office issues such a…
Get regular updates to your inbox.
